1887

Abstract

Epstein–Barr virus (EBV) is associated with various epithelial malignancies such as nasopharyngeal carcinoma and gastric carcinoma, and causes oral hairy leukoplakia, a productive EBV infection of the differentiated epithelium of the tongue. However, it is not clear by what mechanism EBV infects epithelial cells. We generated a recombinant EBV that expresses enhanced green fluorescent protein in order to monitor EBV entrance into epithelial cells quickly and quantitatively. Using this monitoring system, we examined the roles of gp350 and gp25 in EBV infection of epithelial cells by utilizing soluble forms of the gp350 and gp25 proteins. EBV infection of three of four examined epithelial cell lines, 293, NU-GC-3 and Lovo, was almost completely blocked by pretreatment of cells with a soluble form of gp350 (designated gp350Ig), and this blockage was dependent on the CD21-binding region of gp350. On the other hand, infection of the other epithelial cell line, AGS, was not inhibited at all by pretreatment with gp350Ig. Moreover, we found that a soluble form of gp25 (designated gp25Ig) preferentially bound to epithelial cells rather than B cells, and pretreatment of cells with gp25Ig substantially blocked EBV infection of some epithelial cells. These results indicate the existence of two distinct pathways in EBV infection of epithelial cells, a gp350-dependent pathway and a gp350-independent pathway, and that gp25 can play a role in the infection of some epithelial cells.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-82-10-2373
2001-10-01
2020-07-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/82/10/0822373a.html?itemId=/content/journal/jgv/10.1099/0022-1317-82-10-2373&mimeType=html&fmt=ahah

References

  1. Akiyama S., Amo H., Watanabe T., Matsuyama M., Sakamoto J., Imaizumi M., Ichihashi H., Kondo T., Takagi H.. 1988; Characteristics of three human gastric cancer cell lines, NU-GC-2, NU-GC-3 and NU-GC-4. Japanese Journal of Surgery18:438–446
    [Google Scholar]
  2. Baer R., Bankier A. T., Biggin M. D., Deininger P. L., Farrell P. J., Gibson T. J., Hatfull G., Hudson G. S., Satchwell S. C., Seguin C., Tuffnell P. S., Barrell B. G.. 1984; DNA sequence and expression of the B95-8 Epstein–Barr virus genome. Nature310:207–211
    [Google Scholar]
  3. Barranco S. C., Townsend C. M. Jr, Casartelli C., Macik B. G., Burger N. L., Boerwinkle W. R., Gourley W. K.. 1983; Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Research43:1703–1709
    [Google Scholar]
  4. Drewinko B., Romsdahl M. M., Yang L. Y., Ahearn M. J., Trujillo J. M.. 1976; Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Research36:467–475
    [Google Scholar]
  5. Fingeroth J. D., Weis J. J., Tedder T. F., Strominger J. L., Biro P. A., Fearon D. T.. 1984; Epstein–Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proceedings of the National Academy of Sciences, USA81:4510–4514
    [Google Scholar]
  6. Fingeroth J. D., Diamond M. E., Sage D. R., Hayman J., Yates J. L.. 1999; CD21-dependent infection of an epithelial cell line, 293, by Epstein–Barr virus. Journal of Virology73:2115–2125
    [Google Scholar]
  7. Frade R., Barel M., Ehlin-Henriksson B., Klein G.. 1985; gp140, the C3d receptor of human B lymphocytes, is also the Epstein–Barr virus receptor. Proceedings of the National Academy of Sciences, USA82:1490–1493
    [Google Scholar]
  8. Fukayama M., Hayashi Y., Iwasaki Y., Chong J., Ooba T., Takizawa T., Koike M., Mizutani S., Miyaki M., Hirai K.. 1994; Epstein–Barr virus-associated gastric carcinoma and Epstein–Barr virus infection of the stomach. Laboratory Investigation71:73–81
    [Google Scholar]
  9. Gluzman Y.. 1981; SV40-transformed simian cells support the replication of early SV40 mutants. Cell23:175–182
    [Google Scholar]
  10. Graham F. L., Smiley J., Russell W. C., Nairn R.. 1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology36:59–74
    [Google Scholar]
  11. Greenspan J. S., Greenspan D., Lennette E. T., Abrams D. I., Conant M. A., Petersen V., Freese U. K.. 1985; Replication of Epstein–Barr virus within the epithelial cells of oral ‘hairy’ leukoplakia, an AIDS-associated lesion. New England Journal of Medicine313:1564–1571
    [Google Scholar]
  12. Haan K. M., Kwok W. W., Longnecker R., Speck P.. 2000; Epstein–Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor. Journal of Virology74:2451–2454
    [Google Scholar]
  13. Haddad R. S., Hutt-Fletcher L. M.. 1989; Depletion of glycoprotein gp85 from virosomes made with Epstein–Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells. Journal of Virology63:4998–5005
    [Google Scholar]
  14. Imai S., Koizumi S., Sugiura M., Tokunaga M., Uemura Y., Yamamoto N., Tanaka S., Sato E., Osato T.. 1994; Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein–Barr virus latent infection protein. Proceedings of the National Academy of Sciences, USA91:9131–9135
    [Google Scholar]
  15. Imai S., Nishikawa J., Takada K.. 1998; Cell-to-cell contact as an efficient mode of Epstein–Barr virus infection of diverse human epithelial cells. Journal of Virology72:4371–4378
    [Google Scholar]
  16. Janz A., Oezel M., Kurzeder C., Mautner J., Pich D., Kost M., Hammerschmidt W., Delecluse H.-J.. 2000; Infection of Epstein–Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. Journal of Virology74:10142–10152
    [Google Scholar]
  17. Kieff E.. 1996; Epstein–Barr virus and its replication. In Fields Virology pp2343–2396 Edited by Fields B. N., Knipe D. M., Howley P. M.. Philadelphia: Lippincott–Raven;
    [Google Scholar]
  18. Li Q., Turk S. M., Hutt-Fletcher L. M.. 1995; The Epstein–Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. Journal of Virology69:3987–3994
    [Google Scholar]
  19. Li Q., Spriggs M. K., Kovats S., Turk S. M., Comeau M. R., Nepom B., Hutt-Fletcher L. M.. 1997; Epstein–Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. Journal of Virology71:4657–4662
    [Google Scholar]
  20. Linsley P. S., Brady W., Grosmaire L., Aruffo A., Damle N. K., Ledbetter J. A.. 1991a; Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. Journal of Experimental Medicine173:721–730
    [Google Scholar]
  21. Linsley P. S., Brady W., Urnes M., Grosmaire L. S., Damle N. K., Ledbetter J. A.. 1991b; CTLA-4 is a second receptor for the B cell activation antigen B7. Journal of Experimental Medicine174:561–569
    [Google Scholar]
  22. Miller N., Hutt-Fletcher L. M.. 1988; A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein–Barr virus. Journal of Virology62:2366–2372
    [Google Scholar]
  23. Molesworth S. J., Lake C. M., Borza C. M., Turk S. M., Hutt-Fletcher L. M.. 2000; Epstein–Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. Journal of Virology74:6324–6332
    [Google Scholar]
  24. Nemerow G. R., Mold C., Schwend V. K., Tollefson V., Cooper N. R.. 1987; Identification of gp350 as the viral glycoprotein mediating attachment of Epstein–Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. Journal of Virology61:1416–1420
    [Google Scholar]
  25. Nemerow G. R., Houghten R. A., Moore M. D., Cooper N. R.. 1989; Identification of an epitope in the major envelope protein of Epstein–Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell56:369–377
    [Google Scholar]
  26. Nishikawa J., Imai S., Oda T., Kojima T., Okita K., Takada K.. 1999; Epstein–Barr virus promotes epithelial cell growth in the absence of EBNA2 and LMP1 expression. Journal of Virology73:1286–1292
    [Google Scholar]
  27. Oda T., Imai S., Chiba S., Takada K.. 2000; Epstein–Barr virus lacking glycoprotein gp85 cannot infect B cells and epithelial cells. Virology276:52–58
    [Google Scholar]
  28. Parker B. D., Bankier A. T., Satchwell S. C., Barrell B. G., Farrell P. J.. 1990; Sequence and transcription of Raji Epstein–Barr virus DNA spanning the B95-8 deletion region. Virology179:339–346
    [Google Scholar]
  29. Pulvertaft R. J. V.. 1964; Cytology of Burkitt’s tumor (African lymphoma). Lanceti:238–240
    [Google Scholar]
  30. Rickinson A. B., Kieff E.. 1996; Epstein–Barr virus. In Fields Virology pp2397–2446 Edited by Fields B. N., Knipe D. M., Howley P. M. Philadelphia: Lippincott–Raven;
    [Google Scholar]
  31. Shibata D., Weiss L. M.. 1992; Epstein–Barr virus-associated gastric adenocarcinoma. American Journal of Pathology140:769–774
    [Google Scholar]
  32. Shimizu N., Tanabe-Tochikura A., Kuroiwa Y., Takada K.. 1994; Isolation of Epstein–Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt’s lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. Journal of Virology68:6069–6073
    [Google Scholar]
  33. Shimizu N., Yoshiyama H., Takada K.. 1996; Clonal propagation of Epstein–Barr virus (EBV) recombinants in EBV-negative Akata cells. Journal of Virology70:7260–7263
    [Google Scholar]
  34. Spriggs M. K., Armitage R. J., Comeau M. R., Strockbine L., Farrah T., Macduff B., Ulrich D., Alderson M. R., Müllberg J., Cohen J. I.. 1996; The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA- DR β chain and inhibits antigen presentation. Journal of Virology70:5557–5563
    [Google Scholar]
  35. Takada K.. 1984; Cross-linking of cell surface immunoglobulins induces Epstein–Barr virus in Burkitt lymphoma lines. International Journal of Cancer33:27–32
    [Google Scholar]
  36. Takada K., Ono Y.. 1989; Synchronous and sequential activation of latently infected Epstein–Barr virus genomes. Journal of Virology63:445–449
    [Google Scholar]
  37. Takada K., Horinouchi K., Ono Y., Aya T., Osato T., Takahashi M., Hayasaka S.. 1991; An Epstein–Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes5:147–156
    [Google Scholar]
  38. Wang X., Hutt-Fletcher L. M.. 1998; Epstein–Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. Journal of Virology72:158–163
    [Google Scholar]
  39. Wang X., Kenyon W. J., Li Q., Müllberg J., Hutt-Fletcher L. M.. 1998; Epstein–Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. Journal of Virology72:5552–5558
    [Google Scholar]
  40. Yamada A., Murakami M., Ijima K., Yagita H., Okumura K., Komatsu S., Uede T.. 1996; Long-term acceptance of major histocompatibility complex-mismatched cardiac allograft induced by a low dose of CTLA4IgM plus FK506. Microbiology and Immunology40:513–518
    [Google Scholar]
  41. Yoshiyama H., Shimizu N., Takada K.. 1995; Persistent Epstein–Barr virus infection in a human T-cell line: unique program of latent virus expression. EMBO Journal14:3706–3711
    [Google Scholar]
  42. Yoshiyama H., Imai S., Shimizu N., Takada K.. 1997; Epstein–Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. Journal of Virology71:5688–5691
    [Google Scholar]
  43. Young L. S., Lau R., Rowe M., Niedobitek G., Packham G., Shanahan F., Rowe D. T., Greenspan D., Greenspan J. S., Rickinson A. B., Farrell P. J.. 1991; Differentiation-associated expression of the Epstein–Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. Journal of Virology65:2868–2874
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-82-10-2373
Loading
/content/journal/jgv/10.1099/0022-1317-82-10-2373
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error